Recently there have been numerous articles and editorials understandably scrutinizing the increases in pricing of EpiPen produced by Mylan, a generic drug company. The strong reaction to the behavior of Mylan and a few other companies is threatening to impede the ability of R&D-focused innovator companies to provide innovative, life-changing new therapies to patients.
{iframe}http://www.forbes.com/sites/sciencebiz/2016/09/13/biotech-ceos-dont-let-epipen-threaten-innovation/#17427cb6509b{/iframe}